Literature DB >> 14963069

Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.

J C Rodríguez1, L Cebrián, M López, M Ruiz, I Jiménez, G Royo.   

Abstract

OBJECTIVES: The mutant prevention concentration (MPC) has recently been defined to characterize the capacity for severely restricting the selection of resistant mutants during antibiotic treatment. We determined this parameter for ciprofloxacin, levofloxacin, gatifloxacin, moxifloxacin and linezolid in Mycobacterium tuberculosis clinical isolates in our setting.
METHODS: We determined the antibiotic concentration that prevents the selection of resistant mutants following inoculation with a high mycobacteria inoculum on Middlebrook 7H11 plates with serial dilutions of the antibiotics in 224 M. tuberculosis isolates.
RESULTS: Fifty percent of the strains exhibited values of MPC (MPC(50)) lower than 0.8, 0.6, 0.4, 0.4 and 0.6 mg/L for ciprofloxacin, levofloxacin, gatifloxacin, moxifloxacin and linezolid, respectively. If 90% of the strains are considered (MPC(90)), the values are seen to rise to 2, 1.8, 1, 1.2 and 1.2 mg/L, respectively.
CONCLUSIONS: When we compare this parameter with the drug levels in serum and tissue, it can be seen that ciprofloxacin is the least useful of the fluoroquinolones studied, whereas moxifloxacin appears to be the most active. Linezolid exhibits excellent activity against this microorganism (MPC(90) 1.2 mg/L and AUC 140.3 mg.h/L) and this makes us consider that its usefulness in the treatment of this pathology should be thoroughly evaluated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14963069     DOI: 10.1093/jac/dkh119

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  23 in total

Review 1.  A unified anti-mutant dosing strategy.

Authors:  Xilin Zhao; Karl Drlica
Journal:  J Antimicrob Chemother       Date:  2008-06-10       Impact factor: 5.790

Review 2.  Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.

Authors:  Devan Jaganath; H Simon Schaaf; Peter R Donald
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

3.  Distribution of Linezolid in Tuberculosis Lesions in Patients with Spinal Multidrug-Resistant Tuberculosis.

Authors:  Yuan Li; Weijie Dong; Tinglong Lan; Jun Fan; Shibing Qin; Ai Guo
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

4.  Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?

Authors:  Kwok-Chiu Chang; Wing-Wai Yew; Siu-Wai Cheung; Chi-Chiu Leung; Cheuk-Ming Tam; Chi-Hung Chau; Peter Kin-Ho Wen; Raphael Chiu-Yeung Chan
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

5.  A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis.

Authors:  Russell R Kempker; M Tobias Heinrichs; Ketino Nikolaishvili; Irina Sabulua; Nino Bablishvili; Shota Gogishvili; Zaza Avaliani; Brent P Little; Adam Bernheim; Hartmut Derendorf; Henry M Blumberg; Sergo Vashakidze; Charles A Peloquin
Journal:  Eur Respir J       Date:  2018-02-07       Impact factor: 16.671

6.  Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.

Authors:  Lauren M Boak; Jian Li; Craig R Rayner; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

7.  Role of the Cys154Arg Substitution in Ribosomal Protein L3 in Oxazolidinone Resistance in Mycobacterium tuberculosis.

Authors:  Gaëlle Guiewi Makafe; Yuanyuan Cao; Yaoju Tan; Mugweru Julius; Zhiyong Liu; Changwei Wang; Moses M Njire; Xingshan Cai; Tianzhou Liu; Bangxing Wang; Wei Pang; Shouyong Tan; Buchang Zhang; Wing Wai Yew; Gyanu Lamichhane; Jintao Guo; Tianyu Zhang
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

8.  Linezolid for treatment of chronic extensively drug-resistant tuberculosis.

Authors:  Myungsun Lee; Jongseok Lee; Matthew W Carroll; Hongjo Choi; Seonyeong Min; Taeksun Song; Laura E Via; Lisa C Goldfeder; Eunhwa Kang; Boyoung Jin; Hyeeun Park; Hyunkyung Kwak; Hyunchul Kim; Han-Seung Jeon; Ina Jeong; Joon Sung Joh; Ray Y Chen; Kenneth N Olivier; Pamela A Shaw; Dean Follmann; Sun Dae Song; Jong-Koo Lee; Dukhyoung Lee; Cheon Tae Kim; Veronique Dartois; Seung-Kyu Park; Sang-Nae Cho; Clifton E Barry
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

Review 9.  Moxifloxacin: a review of its use in the management of bacterial infections.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis.

Authors:  Kwok-Chiu Chang; Wing-Wai Yew; Cheuk-Ming Tam; Chi-Chiu Leung
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.